Who are The Cancer Letter readers?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

After 45 years of covering oncology, we stopped and asked our readers: who are you?

In a survey sent out to The Cancer Letter’s weekly mailing list, we asked key questions about our readers, their professional degrees, their fields of interest, and their satisfaction with our coverage.

We were pleased to learn that you like us: 83.1% of you rated your satisfaction with our reporting of your areas of interest at a 4 or 5 out of 5, with an average score of 4.1 out of 5 (82%).

We sent the survey to a list of 6,000 readers, and received 419 responses (7%).

story1-1

Of the responses, 37.7% are MDs and 35.6% are PhDs. Within that list, 25 are MD PhDs (6%).

story1-2

*terminal degree

You identified yourselves primarily as clinicians (33.7%), basic scientists (27.2%), and administrators (30.3%)—a surprisingly balanced spread.

story1-3

While this survey didn’t include the thousands of readers at institutions that distribute the PDF internally, we were pleased to learn that you love reading our PDF edition as well as our online content. Redesigned in 2017, our PDF edition has won design awards, and is a primary way many of our readers access The Cancer Letter.

The Cancer Letter has over 200 institutional subscribers.
For login or subscription issues, inquiries about group rates, advertising, or any other administrative questions please contact
katie@cancerletter.com.

story1-4

story1-5

YOU MAY BE INTERESTED IN

In this week's episode of The Cancer Letter Podcast, editor and publisher Paul Goldberg, and associate editor Jacquelyn Cobb revisit two of last week’s most-read stories: the growing recognition that early-onset colorectal cancer requires a new diagnostic mindset, and the life and legacy of Maura Gillison, the scientist whose discovery that most head and neck cancers are driven by HPV transformed the field. 
For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login